UroGen Pharma Ltd. Foreign Pre-Tax Income
UroGen Pharma Ltd. (URGN) reported Foreign Pre-Tax Income of $35.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2026-03-02
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, foreign for fiscal 2025 was $35.00M, a 218.18% increase from fiscal 2024.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was $11.00M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was -$17.90M.
- UroGen Pharma Ltd. income (loss) from continuing operations before income taxes, foreign for fiscal 2022 was -$13.30M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month as first filed |
|---|---|---|
| 2025-12-31 | $35.00M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $11.00M 10-K · filed 2026-03-02 | -$11.00M 10-K · filed 2025-03-10 |
| 2023-12-31 | -$17.90M 10-K · filed 2025-03-10 | |
| 2022-12-31 | -$13.30M 10-K · filed 2024-03-14 | |
| 2021-12-31 | -$10.10M 10-K · filed 2023-03-24 | |
| 2020-12-31 | -$17.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |